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corrected for each patient. With the new 'corrected' errors 
and the other errors measured during follow-up CBCT, 
standard deviation was determined for each patient. 
Then they were added quadratically, ie each individual 
overall deviation were squared, added all squares and from 
the result the standard deviation of random errors (σ) was 
obtained. Finally, for each direction, the formulas of Van 
Herk & de Stroom were applied 
Results: The mean values of the systematic errors of the first 
5 CBCT were:Sver:0,3, Slong: 0,2 y Slat: 0,2. The standard 
deviation of the random errors was: σver: 1.43, σlong: 0.77 y 
σlat: 0.96. The results of applying the formulas of van Herk 





Conclusions: No statistically significant differences were 
found between the values obtained for each of the systems 
for calculating margin expansion. Therefore, we will evaluate 
which of the two will be applied in our patients, considering 
that Stroom formula obtains a margin assuring that 99% of 
CTV is within the 95% isodose and Van Herk formula obtains a 
margin which ensures that 90% of the population receives at 
least 95% of the prescribed dose to the CTV. 
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Purpose/Objective: The application of hypofractionated 
regimen allows to reduce the treatment time of radiotherapy 
(RT) and is theoretically associated with an improvement of 
the probability of cure in patients affected by prostatic 
carcinoma (CAP). However, hypofractionated RT could be 
associated with a higher incidence of late side effects. Many 
studies are currently in progress to assess the effectiveness 
of this irradiation modality, but definitive indications about 
tolerance and efficacy of this method are still missing. The 
aim of this study was the comparison of the therapeutic 
results recorded in two different studies of CAP RT, based on 
different dose fractionation. 
Materials and Methods: In this analysis were included 
patients enrolled in: 1) an observational study on RT of 
prostate +/- seminal vesicles with 3D technique and a dose of 
73.8 Gy (1.8 Gy/fraction); 2) a phase I-II study on RT of 
prostate +/- seminal vesicles with IGRT-IMRT-SIB technique 
and a dose of 65 Gy (2.6 Gy/fraction) +/- radiosurgical boost 
(5 Gy in single fraction). Biochemical recurrence-free survival 
(according to Phoenix-criteria), local control, disease-free 
and overall survival were evaluated using the Kaplan-Meier 
method. Survival curves were compared by logrank test 
(univariate analysis) or Cox Proportional Hazard Method 
(multivariate analysis, considering as covariates: risk class, 
RT-treatment modalities, lenght of hormonal therapy). 
Patients were classified according to NCCN 2014 risk 
categories. 
Results: 326 patients have been included in this comparison. 
The results of the analysis have been reported in the table. 
Also the multivariate analysis showed no difference in terms 
of biochemical and clinical outcomes between the two groups 
of patients (p: NS). 
 
Conclusions: Comparing two prospective studies, a 
hypofractionated treatment +/- stereotactic boost showed 
comparable results in terms of toxicity and biochemical 
outcome to the standard treatment. 
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Purpose/Objective: Postoperative radiotherapy improves 
prognosis in high risk prostate cancer patients. However, 5-
year biochemical recurrence free survival does not exceed 75 
- 80%. On the basis of several randomized trials, showing a 
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significant advantage in patients undergoing exclusive 
radiotherapy associated to adjuvant hormone therapy, this 
treatment could improve outcome even in resected patients.  
However, prospective studies on adjuvant hormone therapy 
in patients treated with radical prostatectomy and 
postoperative radiotherapy are lacking. Also comparisons 
between different adjuvant hormone therapies (LH-RH 
analogue vs antiandrogen) are lacking. Aim of this study was 
to evaluate results in patients treated with radical 
prostatectomy followed by postoperative radiotherapy and 
adjuvant hormone therapy and to compare results in patients 
receiving hormone therapy based on LH-RH analogue vs high 
dose Bicalutamide.  
Materials and Methods: Data were collected from two 
different clinical trials in which patients received adjuvant 
hormone therapy, depending on risk categories, with LH-RH 
analogue or high dose Bicalutamide according to the 
preference of urologist and /or patient. Biochemical 
recurrence free survival (PSA >/= 0,2 ng/ml), local control, 
metastasis free survival and overall survival were evaluated 
with the Kaplan-Meier's method. Survival curves were 
compared with logrank test (univariate analysis) or Cox 
Proportional Hazard Method (multivariate analysis), 
considering as covariates: risk class, dose of radiotherapy and 
hormone therapy duration. Patients were classified according 
to NCCN 2014 category risk. 
Results: 140 patients were included in the analysis (pT3-
4:89.0%; pN1:15.8%; R1:85.0%; Gleason score > 7: 35.7%). The 
results are reported in the table below. The multivariated 
analysis confirmed the lack of correlation between type of 
hormone therapy and biochemical recurrence free survival 
(p: 0.250). 
Conclusions: The combination of adjuvant hormone therapy 
and postoperative radiotherapy improves the biochemical 
outcome compared to standard treatment. The efficacy of 
adjuvant therapy seems not related to hormone therapy 
type. Further studies to reduce the toxicity induced by 
hormone therapy in patients treated with radical 
prostatectomy plus radiotherapy are justified. 
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Purpose/Objective: To assess the relationship between 
rectal hemorrhage and planned dose-volume histogram (DVH) 
parameters in localized prostate cancer patients with 1-6 
years of follow-up after intensity-modulated radiation 
therapy (IMRT). 
Materials and Methods: Between October 2008 and 
September 2012, 124 patients diagnosed with localized 
prostate cancer (D'Amico classification: low-, intermediate-, 
and high-risk rates: 15%, 23%, and 62%, respectively) were 
treated with IMRT. Among these, 94 patients (76%) received 
hormonal therapy (D'Amico classification: low-, intermediate-
, and high-risk: 42%, 46%, and 95%, respectively). One patient 
was lost to follow-up and excluded from the analysis. 
Therefore, we performed a retrospective analysis of 123 
patients. Rectal hemorrhage was graded according to a 
modification of the CTCAE v4.0 as Grade 1, one untreated 
bleeding episode; Grade 2, two or more bleeding episodes; 
and Grade 3, bleeding requiring one or more transfusions 
and/or Argon plasma coagulation (APC). Three groupings of 
DVH parameters were defined, based on the percentage of 
rectum receiving 70Gy (V70), 60Gy (V60) and 40Gy (V40). 
Associations between DVH groupings or clinical 
characteristics and the incidence of rectal hemorrhage of 
Grade ≥2 were evaluated. 
Results: The median follow-up was 27.8 months (range, 10.2-
56.5 months). The mean age was 70 years (range, 49-82 
years). Fifty-eight patients (47%) were treated to 74 Gy, and 
65 (53%) were treated to 78 Gy. Twenty-two patients (18 %) 
experienced Grade ≥2 rectal hemorrhage. Six patients (5%) 
experienced Grade 3 rectal hemorrhage. No Grade 4 or 5 
rectal hemorrhage was observed. The 3-year Grade 3 rectal 
hemorrhage rate was 6.2%. Freedom from Grade ≥2 rectal 
hemorrhage at 3 years was 81% for patients with rectal V70 60 
40 70 10-15%, V60 20-25%, and V40 40-45%; and 59% for patients 
with rectal V70 15-25%, V60 25-35%, and V40 45-65% (p=0.045). 
Conclusions: The rectal DVH groupings were associated with 
rectal hemorrhage after IMRT. The treatment plan should be 
carefully optimized to minimize dose to the rectum.  
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Purpose/Objective: To evaluate feasibility and acute toxicity 
of retreatment in prostate cancer (PC) patients after 
previous radiotherapy (RT) . 
Materials and Methods: From December 2012 to October 
2014, 10 patients with a prior history of pelvic RT were 
treated with Helical Tomotherapy (HT): acute toxicity was 
evaluable in 7 cases. All patients underwent 18F-choline PET 
and pelvis magnetic resonance imaging scans. Neoadiuvant 
hormone therapy was administred. The prior RT course was 
